MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ABVX stock logo

ABVX

Abivax S.A.

$118.37
3.4
 (2.96%)
Exchange:  NASDAQ
Market Cap:  7.761B
Shares Outstanding:  9.272M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Didier Blondel
Full Time Employees:  69
Address: 
5, rue de la Baume
Paris
75008
FR
Website:  https://www.abivax.com
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn’s Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue4,62110,7920
Gross Profit4,57410,792-1,029.690
EBITDA-133,207-171,883-239,703.815
Operating Income-127,376-172,984-240,733.505
Net Income-147,740-176,242-322,836.959

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets327,062205,228584,092.301
Total Liabilities131,052164,644129,081.038
Total Stockholders Equity196,01040,584455,011.262
Total Debt55,46497,36132,079.339
Cash and Cash Equivalents251,942144,221516,465.096

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-100,009-154,072-155,691.783
Capital Expenditure-265-643-136.396
Free Cash Flow-100,275-154,715-155,828.179
Net Income-147,740-176,242-322,836.959
Net Change in Cash224,992-107,721389,361.102

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)1,388,918.965Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)2,129,304.068Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,743,919.127Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-1,277,582.440Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-833,351.379Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-1,046,351.476Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)412,926.901Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)722,842.826Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)561,525.548Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)45,351,043.884Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)69,526,131.232Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)56,942,524.980Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)8.080Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)10.400Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)5.940Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)7Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
?Enterprise Value
 (TTM)
: 
  ?EV/FCF
 (TTM)
: 
?Dividend Yield
 (TTM)
: 
  ?Payout Ratio
 (TTM)
: 
?ROE
 (TTM)
: 
  ?ROIC
 (TTM)
: 
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
?P/B
 (TTM)
: 
  ?Current Ratio
 (TTM)
: 

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate ABVX Intrinsic Value

Common questions about ABVX valuation

Is ABVX (ABVX) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for ABVX (ABVX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ABVX a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ABVX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ABVX’s P/E ratio?

You can see ABVX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ABVX?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ABVX a good long-term investment?

Whether ABVX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ABVX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

2.96
MARKETSnap

Trading Metrics:

Open:    Previous Close: 
Day Low:    Day High: 
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
Alger Mid Cap Growth Fund Q4 2025 Portfolio Update
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Prediction: This Healthcare Stock Could Soar by 72% in 2026
Abivax: Don't Just Buy The Rumor, Buy The Fundamentals
France has had no request for investment approval in biotech Abivax - official

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read